Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 10 valent pneumococcal conjugate (vaccine), 10 valent pneumococcal conjugate
10 valent pneumococcal conjugate vaccine · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| 10 valent pneumococcal conjugate (vaccine) | BIOLOGICAL | - |
| 10 valent pneumococcal conjugate vaccine | BIOLOGICAL | - |
| Infanrix Hexa | BIOLOGICAL | - |
| Rotarix | BIOLOGICAL | - |
| Paracetamol | DRUG | - |
Inclusion Criteria: * a healthy male or female, 12-14 months of age at the time of first vaccination, who received at least one dose of pneumococcal conjugate vaccine during study 105553 and with written informed consent obtained from the parent/guardian of the subject. Exclusion Criteria: * use ...
The 10 valent pneumococcal conjugate vaccine is an investigational vaccine developed by GSK plc for preventing streptococcal and other infections. It is designed to protect against ten pneumococcal serotypes and has been studied in infants and young children, including as a booster dose following primary vaccination.
It is being developed for the prevention of pneumococcal infections, including streptococcal infections, in young children. Clinical studies have evaluated its use alongside standard infant vaccines and as a booster dose in children from 12 months of age, with healthy volunteers enrolled in the trials.
GSK plc, which trades under the ticker GSK, is the developer of the 10 valent pneumococcal conjugate vaccine. The vaccine is part of GSK's pneumococcal conjugate vaccine program and has been evaluated in Phase 3 clinical studies conducted in Europe.
The 10 valent pneumococcal conjugate vaccine is in Phase 3 clinical development. It is investigational and has not been approved by the FDA. Its completed Phase 3 trials enrolled approximately 400 and 390 participants respectively, and no active trials are currently listed for this asset.
Two completed Phase 3 trials have studied the vaccine. NCT00370318 evaluated prophylactic antipyretic treatment in children receiving pneumococcal conjugate and standard infant vaccines in Czechia, enrolling 400 participants. NCT00370227 assessed the safety and immunogenicity of a booster dose in Finland, enrolling 390 participants from 12 months of age.
Yes. The 10 valent pneumococcal conjugate vaccine is also referred to as 10 valent pneumococcal conjugate (vaccine) or simply 10 valent pneumococcal conjugate. These names refer to the same GSK plc vaccine candidate in Phase 3 development for pneumococcal and streptococcal infections.